24 października 2016r.
Zapytanie ofertowe: stanowisko „Manager ds. rozwoju leku” w projekcie 3/1.1.1/2016.

 

Until now dendrimers have been used as drug delivery carriers. Our discovery indicates that maltotriose modification of these nanomolecules gives them a new value: they become an active substance – the drug itself. The nanoparticle prepared in such a way can cause the death of leukemic cells while not damaging healthy blood cells. The studies with the use of 4th generation-modified dendrimers have shown that they trigger apoptotis in leukemic cells which is impaired, thus reducing the number of leukemic cells. In addition, those glycodendrimers show no toxicity to other blood components (red blood cells and pellets), allowing an effective biodistribution and an efficient specificity. We’ve obtained positive results on CLL cells from patients and on customer cell lines in-vitro. GeneaMed is now conducting pre-clinical testing of patented and other new drug candidates. 

Our invention won the Gold Medal at the International Invention Exhibition „Concours Lépine 2013” in Paris organized by „Association des inventeurs et Fabricants Français”

• WO 2014088435 A1for dendrimer PPI-G4-OS-Mal-III,
• WO 2014088434 A1 for dendrimer PPI-G4-DS-Mal-III,

concerning the application of maltotriose-coated 4th generation polypropyleneimine dendrimers for treating neoplastic proliferative diseases, particularly chronic lymphocytic leukemia (CLL).

Send us a message